Quantcast
Last updated on April 16, 2014 at 11:24 EDT

Latest BK virus Stories

2013-04-25 08:34:16

May 11, 2013 Grand Hotel Bristol, Stresa, Italy ATLANTA, April 25, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it will update the scientific and medical community on the development program for IkT-001Pro. IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal...

2013-02-19 08:31:46

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the BMT Tandem Meetings supporting the broad spectrum antiviral activity and emerging safety profile of CMX001. CMX001 is an oral nucleotide lipid-conjugate anticipated to start a Phase 3 study later this year. "These findings demonstrate CMX001's potential to be a safe and...

2013-02-04 08:25:18

RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing antivirals in areas of high unmet medical need, today announced that three abstracts related to the broad-spectrum antiviral compound CMX001 will be presented at the BMT Tandem Meetings being held February 13-17 in Salt Lake City. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the...

2012-11-26 08:23:53

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive Officer Kenneth I. Moch will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA. His presentation will include an update on the company's clinical pipeline, including its lead development compound, CMX001, which was named by conference organizers a "Top 10 Project to...

2012-07-23 06:26:19

RESEARCH TRIANGLE PARK, N.C., July 23, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the presentation of data showing that its lead antiviral compound, CMX001, has the potential to reduce end-organ damage associated with BK virus (BKV) in hematopoietic stem cell transplant (HSCT) recipients. This new retrospective analysis, entitled "CMX001, a Novel Broad Spectrum Antiviral, May Mitigate Signs of BK...

2012-07-09 06:28:09

RESEARCH TRIANGLE PARK, N.C., July 9, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the 24th International Congress of the Transplantation Society being held July 15-19th, 2012 at the International Congress Centre Berlin in Berlin, Germany. The poster presentation, entitled "CMX001, a Novel Broad Spectrum Antiviral, May Mitigate Signs of BK Virus (BKV) Associated Bladder...

2011-11-15 10:12:00

MADISON, N.J. and CYPRESS, Calif., Nov. 15, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Focus Diagnostics business has CE marked its new Simplexa Cytomegalovirus (CMV) molecular test kit on the 3M(TM) Integrated Cycler for distribution to approximately 35 countries in Europe. The test is designed to enable hospital labs to perform advanced molecular testing for...

2011-11-11 11:06:00

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA. V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial...

2011-04-28 09:29:00

MADISON, N.J., and CYPRESS, Calif., April 28, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that two new Simplexa-branded molecular test kits developed by its Focus Diagnostics business have been CE marked for distribution to approximately 35 countries in Europe. The test kits, designed to enable hospital labs to perform advanced molecular testing for Epstein-Barr (EBV) and BK...

2011-02-24 08:30:00

DURHAM, N.C., Feb. 24, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus (AdV) infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001. Oral CMX001 was administered under an Emergency Investigational New Drug Application (EIND) to a severely immunocompromised pediatric stem cell patient following...


Latest BK virus Reference Libraries

2011-01-05 16:14:54

The BK virus, a member of the polyomavirus family, has no major consequences of infected except with those that are immunocomprimised or immunosuppressed. The virus was first isolated in 1971 from the urine sample of a renal transplant patient whose initials were B.K. Similar in genome sequences to the JCV virus they are most easily identified and differentiated from each other through serological tests using specific antibodies or through PCR based genotyping approach. Most people are...

More Articles (1 articles) »